APOA1 and infection: These studies helped develop a new pharmaceutical agent to treat the cytokine storm and hyperinflammation in acute and chronic inflammatory disease by protecting HDL and apoA-I from glycoxidation attack, maximizing its anti-infection and anti-inflammation activity.